Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 10, 2010, Pages 1926-1934

  Kampmeier, Florian ^a   Niesen, Judith ^a   Koers, Alexander ^a   Ribbert, Markus ^a   Brecht, Andreas ^b   Fischer, Rainer ^a,c   Kießling, Fabian ^c   Barth, Stefan ^a,c   Thepen, Theo ^a  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b Covalys Biosciences AG ^*  (Switzerland)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

HAGT (SNAP) tag; Molecular imaging; NIR optical imaging; Single chain antibody; Site specific labelling; Tumour targeting

Indexed keywords

6 O BENZYLGUANINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SNARE PROTEIN; COLORING AGENT; DNA ALKYLTRANSFERASE; HYBRID PROTEIN; TRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BINDING SITE; CONTROLLED STUDY; COVALENT BOND; ENZYME SUBSTRATE; FEMALE; FLUORESCENCE IMAGING; GENE CONSTRUCT; KIDNEY CLEARANCE; MOLECULAR PROBE; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL TRANSFORMATION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIGHT RELATED PHENOMENA; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; PATHOLOGY; PROTEIN TRANSPORT; SKIN TUMOR; TIME; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORING AGENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; OPTICAL PROCESSES; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; SKIN NEOPLASMS; TIME FACTORS;

EID: 79952113111     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1482-5     Document Type: Article

References (29)

1. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-13.
2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
3. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009;2009:567486.
4. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
5. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
6. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13:6579-84.
7. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-8.
8. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003;63:7870-5.
9. Diagaradjane P, Orenstein-Cardona JM, Colón-Casasnovas NE, Deorukhkar A, Shentu S, Kuno N, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 2008;14:731-41.
10. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 2007;9:1021-9.
11. Kampmeier F, Ribbert M, Nachreiner T, Dembski S, Beaufils F, Brecht A, et al. Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem 2009.
12. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50-62.
13. Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, et al. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008;7:726-33.
14. Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Müller J, Ischenko I, et al. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 2005;15:305-13.
15. Kindermann M, George N, Johnsson N, Johnsson K. Covalent and selective immobilization of fusion proteins. J Am Chem Soc 2003;125:7810-1.
16. Keppler A, Kindermann M, Gendreizig S, Pick H, Vogel H, Johnsson K. Labeling of fusion proteins of O6-alkylguanine-DNA alkyltransferase with small molecules in vivo and in vitro. Methods 2004;32:437-44.
17. Klimka A, Barth S, Matthey B, Roovers RC, Lemke H, Hansen H, et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 1999;80:1214-22.
18. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromo-lecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
19. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
20. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25:1165-70.
21. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 2000;60:6964-71.
22. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford 3rd WF, Houston LL, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599-605.
23. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36.
24. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13:603-8.
25. Schneider DW, Heitner T, Alicke B, Light DR, McLean K, Satozawa N, et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med 2009;50:435-43.
26. Withrow KP, Gleysteen JP, Safavy A, Skipper J, Desmond RA, Zinn K, et al. Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg 2007;137:729-34.
27. Cuesta AM, Sánchez-Martín D, Sanz L, Bonet J, Compte M, Kremer L, et al. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One 2009;4:e5381.
28. Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 2008;35:151-8.
29. Tolmachev V, Friedman M, Sandström M, Eriksson TL, Rosik D, Hodik M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 2009;50:274-83.